Axsome Therapeutics (AXSM) Stock
Biotech firm developing treatments for depression migraine and ADHD. Here's the price, business snapshot, and what's worth knowing about Axsome Therapeutics in June 2026.
Axsome Therapeutics (NASDAQ: AXSM) is a biopharmaceutical company focused on developing and commercialising therapies for central nervous system (CNS) disorders. The company has brought products to market — notably treatments addressing major depressive disorder and attention deficit hyperactivity disorder — while advancing a clinical-stage pipeline targeting migraine and other CNS indications. Investors should note the firm’s prospects are shaped by product uptake, payer reimbursement, regulatory and clinical trial outcomes, and execution of its commercial strategy. Like many biotech companies, Axsome faces substantial R&D costs and potential earnings volatility; successful trial readouts or approvals can be material catalysts, but setbacks are possible. With a market capitalisation of about $6.56bn, the stock offers growth potential tied to both current product revenues and pipeline progress. This summary is educational only and not investment advice; investors should assess suitability, diversify and consider professional guidance where appropriate.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Axsome Therapeutics' stock, anticipating it could reach a higher price.
Financial Health
Axsome Therapeutics is generating strong revenue and cash flow, indicating healthy financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring AXSM
Early Alzheimer's Detection: Could Blood Tests Replace Scans?
The FDA's approval of Roche and Eli Lilly's blood test marks a pivotal shift toward early and accessible Alzheimer's diagnosis in primary care. This breakthrough is expected to accelerate growth for companies in the diagnostics sector and expand the market for new Alzheimer's treatments.
Published: 14 October 2025
Explore BasketWhy You’ll Want to Watch This Stock
Commercialisation Phase
Approved products offer near-term revenue potential, but growth depends on uptake and reimbursement — performance can vary and is not guaranteed.
Pipeline Catalysts
Clinical programmes for migraine and other CNS conditions could drive value if trials succeed, though clinical outcomes are inherently uncertain.
Market Positioning
At roughly $6.56bn market cap, Axsome’s trajectory depends on market access, partnerships and execution; biotech stocks can be volatile and subject to binary events.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.